Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.78, $0.11 better than the analyst estimate of $1.67. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.74 billion.

GUIDANCE:

Gilead Sciences sees FY2018 revenue of $20-21 billion, versus the consensus of $21.97 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.